Filing Details

Accession Number:
0001140361-17-045703
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-12-11 16:10:49
Reporting Period:
2017-12-07
Accepted Time:
2017-12-11 16:10:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012477 Avadel Pharmaceuticals Plc AVDL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1144178 S Michael Anderson Block 10-1, Blanchardstown
Corporate Park, Ballycoolin
Dublin L2 15
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Adss Acquisiton 2017-12-07 5,000 $8.86 234,750 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Adss Stock Option (right to buy) $6.93 2022-03-08 275,000 275,000 Direct
Adss Stock Option (right to buy) $4.07 2023-02-01 80,500 80,500 Direct
Adss Stock Option (right to buy) $16.30 2024-12-11 200,000 200,000 Direct
Adss Stock Option (right to buy) $14.35 2025-12-10 200,000 200,000 Direct
Adss Stock Option (right to buy) $10.40 2026-12-14 200,000 200,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2022-03-08 275,000 275,000 Direct
2023-02-01 80,500 80,500 Direct
2024-12-11 200,000 200,000 Direct
2025-12-10 200,000 200,000 Direct
2026-12-14 200,000 200,000 Direct
Footnotes
  1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.84 to $8.86, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
  3. Includes (a) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (c) 30,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
  4. Options became exercisable in four equal amounts over the first four anniversaries after the 03/08/2012 grant date.
  5. Options became exercisable in four equal amounts over the first four anniversaries after the 02/01/2013 grant date.
  6. Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
  7. Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
  8. Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.